Cipla and Alkem Laboratories in final lap to buy SMT

Drugmakers Cipla and Alkem Laboratories are frontrunners to acquire a controlling stake in Sahajanand Medical Technologies (SMT), India's largest cardiac stent maker. The deal values SMT at Rs 3,500-4,000 crore.

“Drugmakers Cipla and Alkem Laboratories have emerged as the frontrunners to acquire a controlling stake in Sahajanand Medical Technologies (SMT), India's largest cardiac stent maker.”m.economictimes.com

• 1 source
• m.economictimes.comCipla, Alkem Laboratories in final lap to buy SMT - The Economic TimesReghu BalakrishnanOct 15, 2024

Summarized from public sources; check the original articles before acting on it.